| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,397 |
34,545 |
$3.36M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,855 |
5,149 |
$686K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,391 |
5,172 |
$568K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,452 |
4,272 |
$468K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,380 |
3,890 |
$421K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,693 |
2,571 |
$308K |
| 90686 |
|
6,845 |
6,526 |
$150K |
| D1206 |
Topical application of fluoride varnish |
4,218 |
3,476 |
$102K |
| 92551 |
|
9,438 |
9,043 |
$88K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,710 |
4,266 |
$57K |
| 90670 |
|
2,022 |
1,935 |
$45K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
867 |
805 |
$43K |
| 96127 |
|
12,693 |
10,103 |
$41K |
| 96160 |
|
19,615 |
17,118 |
$41K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,188 |
1,459 |
$35K |
| 90647 |
|
1,178 |
1,127 |
$26K |
| 90723 |
|
1,131 |
1,077 |
$25K |
| 99177 |
|
3,159 |
3,041 |
$15K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
916 |
878 |
$11K |
| 99173 |
|
3,958 |
3,778 |
$8K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
360 |
344 |
$8K |
| 90677 |
|
328 |
307 |
$8K |
| 90651 |
|
368 |
351 |
$8K |
| 90633 |
|
306 |
294 |
$7K |
| 90734 |
|
291 |
274 |
$6K |
| 99215 |
Prolong outpt/office vis |
27 |
26 |
$5K |
| 96161 |
|
1,868 |
1,752 |
$5K |
| 90681 |
|
170 |
158 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
79 |
69 |
$4K |
| 94760 |
|
2,387 |
2,000 |
$3K |
| 87807 |
|
312 |
267 |
$3K |
| 93786 |
|
133 |
120 |
$3K |
| 90381 |
|
16 |
13 |
$2K |
| 99381 |
|
13 |
12 |
$1K |
| 99070 |
|
558 |
413 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
85 |
66 |
$1K |
| 99051 |
|
449 |
394 |
$963.16 |
| 90715 |
|
42 |
41 |
$931.20 |
| 90698 |
|
40 |
40 |
$931.20 |
| 90710 |
|
14 |
14 |
$325.92 |
| 90696 |
|
14 |
14 |
$325.92 |
| 90700 |
|
12 |
12 |
$279.36 |
| 94664 |
|
16 |
12 |
$112.00 |
| 81003 |
|
132 |
125 |
$107.36 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
83 |
65 |
$34.87 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
33 |
25 |
$21.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
617 |
573 |
$6.30 |
| 99072 |
|
133 |
111 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
14 |
14 |
$0.00 |
| 99000 |
|
79 |
64 |
$0.00 |